KR102594510B1 - Cosmetic composition including human adipocyte conditioned media extract and manufacturing method thereof - Google Patents
Cosmetic composition including human adipocyte conditioned media extract and manufacturing method thereof Download PDFInfo
- Publication number
- KR102594510B1 KR102594510B1 KR1020230009796A KR20230009796A KR102594510B1 KR 102594510 B1 KR102594510 B1 KR 102594510B1 KR 1020230009796 A KR1020230009796 A KR 1020230009796A KR 20230009796 A KR20230009796 A KR 20230009796A KR 102594510 B1 KR102594510 B1 KR 102594510B1
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- cosmetic composition
- culture fluid
- cell culture
- ceramide
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 130
- 239000002537 cosmetic Substances 0.000 title claims abstract description 110
- 239000000284 extract Substances 0.000 title claims abstract description 54
- 210000001789 adipocyte Anatomy 0.000 title claims abstract description 50
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 27
- 239000003636 conditioned culture medium Substances 0.000 title 1
- 239000012930 cell culture fluid Substances 0.000 claims abstract description 54
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 22
- 210000000130 stem cell Anatomy 0.000 claims abstract description 14
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 83
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims description 42
- 229940032094 squalane Drugs 0.000 claims description 42
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims description 39
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims description 39
- 229940106189 ceramide Drugs 0.000 claims description 39
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims description 39
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims description 39
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 28
- 239000003995 emulsifying agent Substances 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 239000002105 nanoparticle Substances 0.000 claims description 23
- 238000003756 stirring Methods 0.000 claims description 22
- 238000004945 emulsification Methods 0.000 claims description 18
- 239000002994 raw material Substances 0.000 claims description 16
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 15
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 15
- 238000010438 heat treatment Methods 0.000 claims description 15
- 229960003966 nicotinamide Drugs 0.000 claims description 15
- 235000005152 nicotinamide Nutrition 0.000 claims description 15
- 239000011570 nicotinamide Substances 0.000 claims description 15
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 14
- 229960005305 adenosine Drugs 0.000 claims description 14
- 239000001140 aloe barbadensis leaf extract Substances 0.000 claims description 14
- 229920002674 hyaluronan Polymers 0.000 claims description 14
- 229960003160 hyaluronic acid Drugs 0.000 claims description 14
- 239000002245 particle Substances 0.000 claims description 14
- 239000008213 purified water Substances 0.000 claims description 12
- AQGZJQNZNONGKY-UHFFFAOYSA-N 1-[4-(2,5-dioxopyrrol-1-yl)phenyl]pyrrole-2,5-dione Chemical compound O=C1C=CC(=O)N1C1=CC=C(N2C(C=CC2=O)=O)C=C1 AQGZJQNZNONGKY-UHFFFAOYSA-N 0.000 claims description 11
- 239000003205 fragrance Substances 0.000 claims description 10
- 239000004094 surface-active agent Substances 0.000 claims description 10
- 239000000839 emulsion Substances 0.000 claims description 9
- 239000003002 pH adjusting agent Substances 0.000 claims description 9
- 239000003755 preservative agent Substances 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 7
- 239000003381 stabilizer Substances 0.000 claims description 7
- 230000002335 preservative effect Effects 0.000 claims description 6
- MIUIRGGKIICMBP-NFOZDHADSA-N [27-oxo-27-[[(2s,3s,4r)-1,3,4-trihydroxyoctadecan-2-yl]amino]heptacosyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)[C@H](O)CCCCCCCCCCCCCC MIUIRGGKIICMBP-NFOZDHADSA-N 0.000 claims description 5
- 229940048864 ceramide 1 Drugs 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 4
- 229940093441 palmitoyl oligopeptide Drugs 0.000 claims description 4
- AJLNZWYOJAWBCR-OOPVGHQCSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-car Chemical compound OC(=O)CC[C@H](NC(C)=O)C(=C)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O AJLNZWYOJAWBCR-OOPVGHQCSA-N 0.000 claims description 3
- BYUQATUKPXLFLZ-UIOOFZCWSA-N CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 Chemical compound CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 BYUQATUKPXLFLZ-UIOOFZCWSA-N 0.000 claims description 3
- 229940095094 acetyl hexapeptide-8 Drugs 0.000 claims description 3
- 108010006338 acetyl-glutamyl-glutamyl-methionyl-glutaminyl-arginyl-argininamide Proteins 0.000 claims description 3
- QMIFIFIYYPUVNU-ACMTZBLWSA-L copper (2S)-6-amino-2-[[(2S)-2-[(2-aminoacetyl)amino]-3-imidazol-1-id-4-ylpropanoyl]amino]hexanoate Chemical compound [Cu+2].NCCCC[C@@H](C([O-])=O)NC(=O)[C@@H](NC(=O)CN)CC1=C[N-]C=N1 QMIFIFIYYPUVNU-ACMTZBLWSA-L 0.000 claims description 3
- 239000003860 topical agent Substances 0.000 claims 1
- 238000005303 weighing Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 29
- 239000012531 culture fluid Substances 0.000 abstract description 5
- 210000003491 skin Anatomy 0.000 description 52
- 230000037303 wrinkles Effects 0.000 description 24
- 230000006872 improvement Effects 0.000 description 20
- 102000008186 Collagen Human genes 0.000 description 17
- 108010035532 Collagen Proteins 0.000 description 17
- 229920001436 collagen Polymers 0.000 description 17
- 230000003020 moisturizing effect Effects 0.000 description 17
- 230000015572 biosynthetic process Effects 0.000 description 15
- 238000009472 formulation Methods 0.000 description 13
- 230000000052 comparative effect Effects 0.000 description 12
- 230000002087 whitening effect Effects 0.000 description 11
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 230000008591 skin barrier function Effects 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 7
- 210000000577 adipose tissue Anatomy 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 239000006210 lotion Substances 0.000 description 7
- 230000007423 decrease Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 5
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 5
- 210000002744 extracellular matrix Anatomy 0.000 description 5
- 230000036074 healthy skin Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 230000009759 skin aging Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000003708 ampul Substances 0.000 description 4
- 210000002808 connective tissue Anatomy 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 210000004927 skin cell Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 229940075529 glyceryl stearate Drugs 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000011859 microparticle Substances 0.000 description 3
- 239000007908 nanoemulsion Substances 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 230000037394 skin elasticity Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 229940015975 1,2-hexanediol Drugs 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- JTHZUSWLNCPZLX-UHFFFAOYSA-N 6-fluoro-3-methyl-2h-indazole Chemical compound FC1=CC=C2C(C)=NNC2=C1 JTHZUSWLNCPZLX-UHFFFAOYSA-N 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 2
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 102000007547 Laminin Human genes 0.000 description 2
- 108010085895 Laminin Proteins 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 229940008099 dimethicone Drugs 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- -1 glucosaminoglycan Proteins 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000037373 wrinkle formation Effects 0.000 description 2
- 229940043375 1,5-pentanediol Drugs 0.000 description 1
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
- NKEQOUMMGPBKMM-UHFFFAOYSA-N 2-hydroxy-2-[2-(2-hydroxy-3-octadecanoyloxypropoxy)-2-oxoethyl]butanedioic acid Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CC(O)(C(O)=O)CC(O)=O NKEQOUMMGPBKMM-UHFFFAOYSA-N 0.000 description 1
- NCZPCONIKBICGS-UHFFFAOYSA-N 3-(2-ethylhexoxy)propane-1,2-diol Chemical compound CCCCC(CC)COCC(O)CO NCZPCONIKBICGS-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015535 Euphoric mood Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 101100366137 Mesembryanthemum crystallinum SODCC.1 gene Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- OQILCOQZDHPEAZ-UHFFFAOYSA-N Palmitinsaeure-octylester Natural products CCCCCCCCCCCCCCCC(=O)OCCCCCCCC OQILCOQZDHPEAZ-UHFFFAOYSA-N 0.000 description 1
- 101100096142 Panax ginseng SODCC gene Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 108010081750 Reticulin Proteins 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 229940073669 ceteareth 20 Drugs 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 229940074979 cetyl palmitate Drugs 0.000 description 1
- 230000036570 collagen biosynthesis Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- DTPCFIHYWYONMD-UHFFFAOYSA-N decaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO DTPCFIHYWYONMD-UHFFFAOYSA-N 0.000 description 1
- 210000001047 desmosome Anatomy 0.000 description 1
- REZZEXDLIUJMMS-UHFFFAOYSA-M dimethyldioctadecylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC REZZEXDLIUJMMS-UHFFFAOYSA-M 0.000 description 1
- PKPOVTYZGGYDIJ-UHFFFAOYSA-N dioctyl carbonate Chemical compound CCCCCCCCOC(=O)OCCCCCCCC PKPOVTYZGGYDIJ-UHFFFAOYSA-N 0.000 description 1
- 229940073551 distearyldimonium chloride Drugs 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- CNRDTAOOANTPCG-UHFFFAOYSA-N dodecyl carbamate Chemical compound CCCCCCCCCCCCOC(N)=O CNRDTAOOANTPCG-UHFFFAOYSA-N 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- GJQLBGWSDGMZKM-UHFFFAOYSA-N ethylhexyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(CC)CCCCC GJQLBGWSDGMZKM-UHFFFAOYSA-N 0.000 description 1
- 229940100524 ethylhexylglycerin Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 239000008269 hand cream Substances 0.000 description 1
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940091554 lauryl peg-9 polydimethylsiloxyethyl dimethicone Drugs 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 238000010428 oil painting Methods 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 229940100460 peg-100 stearate Drugs 0.000 description 1
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- RMGVATURDVPNOZ-UHFFFAOYSA-M potassium;hexadecyl hydrogen phosphate Chemical compound [K+].CCCCCCCCCCCCCCCCOP(O)([O-])=O RMGVATURDVPNOZ-UHFFFAOYSA-M 0.000 description 1
- 230000001581 pretranslational effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 101150017120 sod gene Proteins 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940045898 sodium stearoyl glutamate Drugs 0.000 description 1
- JWZSXZWCWMCYPE-RSAXXLAASA-M sodium;(4s)-4-amino-5-dodecoxy-5-oxopentanoate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)[C@@H](N)CCC([O-])=O JWZSXZWCWMCYPE-RSAXXLAASA-M 0.000 description 1
- KDHFCTLPQJQDQI-BDQAORGHSA-M sodium;(4s)-4-amino-5-octadecanoyloxy-5-oxopentanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)OC(=O)[C@@H](N)CCC([O-])=O KDHFCTLPQJQDQI-BDQAORGHSA-M 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- UUJLHYCIMQOUKC-UHFFFAOYSA-N trimethyl-[oxo(trimethylsilylperoxy)silyl]peroxysilane Chemical compound C[Si](C)(C)OO[Si](=O)OO[Si](C)(C)C UUJLHYCIMQOUKC-UHFFFAOYSA-N 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/31—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/606—Nucleosides; Nucleotides; Nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/413—Nanosized, i.e. having sizes below 100 nm
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cosmetics (AREA)
Abstract
Description
본 발명은 인체지방세포배양액 추출물을 함유한 화장료 조성물 및 그 제조 방법에 관한 것으로, 보다 상세하게는 인체 지방조직에서 유래한 줄기세포 배양액인 인체지방세포배양액 추출물과 펩타이드가 고함량으로 함유되어 맑고 투명한 피부로 유지시켜 피부 개선 효과를 도모할 수 있는 인체지방세포배양액 추출물을 함유한 화장료 조성물 및 그 제조 방법에 관한 것이다.The present invention relates to a cosmetic composition containing an extract of human fat cell culture fluid and a method for manufacturing the same. More specifically, the present invention relates to a cosmetic composition containing a high content of human fat cell culture fluid extract and peptide, which is a stem cell culture fluid derived from human adipose tissue, and a clear and transparent cosmetic composition containing a high content of peptides. It relates to a cosmetic composition containing an extract of human fat cell culture fluid that can be maintained in the skin and achieve a skin improvement effect, and a method for producing the same.
화장료의 가장 큰 관심 분야는 노화와 관련된 주름, 색소침착, 탄력감소, 피부 건조화 등이다. 인체의 피부는 노화를 통해 다양한 변화를 겪는다. 먼저, 피부의 구성 성분인 표피, 진피 및 피하조직의 두께가 얇아지고 피부에 탄력을 주는 ECM(Extracellular matrix) 성분이 변하게 된다.The areas of greatest interest in cosmetics are age-related wrinkles, pigmentation, loss of elasticity, and skin dryness. The human skin undergoes various changes through aging. First, the thickness of the epidermis, dermis, and subcutaneous tissue, which are components of the skin, becomes thinner, and the ECM (extracellular matrix) component that gives skin elasticity changes.
피부결합조직을 이루고 있는 콜라겐(collagen), 엘라스틴(elastin), 프로티오글리칸(proteoglycans), 글루코스아미노글리칸(glucosaminoglycan), 라미닌(laminin), 파이브로넥틴(fibronectin) 등이 산화되어 그 기능을 상실함으로써 피부가 탄력을 잃고 주름이 과도하게 형성되면서 노인성 피부로 변화된다.Collagen, elastin, proteoglycans, glucosaminoglycan, laminin, and fibronectin, which make up skin connective tissue, are oxidized and lose their function. As a result, the skin loses elasticity and excessive wrinkles form, turning it into senile skin.
ECM(Extracellular matrix)의 대부분을 차지하는 콜라겐은 나이가 들면서 그 생성이 급격하게 저하되어 주름 생성과 밀접한 연관성을 갖는다. ECM의 결합조직섬유에는 아교섬유, 세망섬유, 탄력섬유가 있으며, 이 중 피부결합조직의 대략 70% 정도를 차지하고 있는 콜라겐은 피부의 섬유아세포에서 대부분 형성된다.Collagen, which makes up most of the ECM (extracellular matrix), has a close relationship with the formation of wrinkles as its production decreases rapidly with age. The connective tissue fibers of ECM include glue fibers, reticular fibers, and elastic fibers. Among these, collagen, which accounts for approximately 70% of skin connective tissue, is mostly formed in skin fibroblasts.
인간은 나이가 들면서 피부 결합조직 내의 콜라겐 함유량이 감소하는데, 이는 콜라겐 합성의 저하와 분해의 촉진에 의한 것이다. 따라서, 콜라겐 생합성의 저하와 콜라겐 분해 촉진은 피부 주름 형성의 가장 큰 원인이라 할 수 있다.As humans age, the collagen content in skin connective tissue decreases, which is due to a decrease in collagen synthesis and acceleration of decomposition. Therefore, a decrease in collagen biosynthesis and acceleration of collagen decomposition can be said to be the biggest cause of skin wrinkle formation.
콜라겐 생합성 과정은 전사 수준과 번역전 수준에 관여하는 많은 요소들에 의해 조절을 받아 변화를 일으키며, 콜라겐 분해는 자외선 등에 의해 콜라겐을 분해하는 콜라겐네이즈(Collagenase)와 같은 MMP(Matrix metalloproteases)의 발현의 촉진으로 콜라겐 분해가 촉진되어 콜라겐 함량이 줄어든다. 아울러, 외부 환경에 의해 콜라겐의 변형이 가속화되면서 피부는 주름이 많아지고 깊어지게 된다.The collagen biosynthetic process is regulated and changed by many factors involved at the transcriptional and pre-translational levels, and collagen decomposition is caused by the expression of MMPs (Matrix metalloproteases) such as collagenase, which decomposes collagen by ultraviolet rays, etc. Stimulation promotes collagen decomposition and reduces collagen content. In addition, as collagen deformation is accelerated by the external environment, wrinkles increase and deepen on the skin.
결과적으로, 피부노화 현상은 세포의 비균질화, 엘라스틴의 소실, 콜라겐의 파괴, 콜라겐 합성의 감소 및 지연 등에 의해 나타난다. 따라서, 피부노화 현상은 피부 표피에서도 일어나지만 주로 진피에서 일어나는 현상이라고 볼 수 있다. 피부는 노화가 진행되기 전에는 피부세포의 생리활성이 활발하여 진피에 있는 섬유아세포에서는 피부의 탄력 및 주름형성 억제에 중요한 콜라겐의 합성과 신진대사가 왕성하다.As a result, skin aging occurs due to cell heterogeneity, loss of elastin, destruction of collagen, and reduction and delay in collagen synthesis. Therefore, skin aging can be seen as a phenomenon that occurs mainly in the dermis, although it also occurs in the skin epidermis. Before skin aging progresses, the physiological activity of skin cells is active, and fibroblasts in the dermis actively synthesize and metabolize collagen, which is important for skin elasticity and suppressing wrinkle formation.
또한, 표피에서는 기저세포의 증식이 활발하고, 피부세포간의 결합을 강화시키는 라미닌, 인테그린, 데스모좀과 같은 결합단백질의 생성이 균형적으로 이루어져 피부 세포조직을 강화시켜 건강한 피부를 유지해 준다.In addition, the proliferation of basal cells is active in the epidermis, and the production of binding proteins such as laminin, integrin, and desmosomes that strengthen the bond between skin cells is balanced, strengthening skin cell tissue and maintaining healthy skin.
그러나, 현대인의 피부는 외부의 각종 유해 환경 및 스트레스에 노출되어 다양한 손상을 받고 있고, 나이가 들면서 피부의 생리활성이 저하되고 손상된 피부의 회복속도가 느려지면서 피부는 탄력저하, 건조, 주름형성, 색소침착, 검버섯, 칙칙함 등의 다양한 피부노화 현상이 나타난다.However, modern people's skin is exposed to various harmful external environments and stresses and undergoes various damage. As the skin's physiological activity decreases and the recovery speed of damaged skin slows as we age, the skin loses elasticity, becomes dry, forms wrinkles, and develops wrinkles. Various skin aging symptoms such as pigmentation, age spots, and dullness appear.
따라서, 화장료의 가장 큰 목표는 피부 세포의 재성을 유도하여 건강한 피부로 가꾸어 노화증세를 개선하는데 있고, 이를 위한 다양한 화장료가 개발되고 있다.Therefore, the biggest goal of cosmetics is to improve the signs of aging by inducing the regeneration of skin cells to create healthy skin, and various cosmetics are being developed for this purpose.
본 발명의 목적은 인체 지방조직에서 유래한 줄기세포 배양액인 인체지방세포배양액 추출물과 펩타이드가 고함량으로 함유되어 맑고 투명한 피부로 유지시켜 피부 개선 효과를 도모할 수 있는 인체지방세포배양액 추출물을 함유한 화장료 조성물 및 그 제조 방법을 제공하는데 있다.The purpose of the present invention is to produce a product containing human fat cell culture fluid extract, which is a stem cell culture fluid derived from human adipose tissue, and human fat cell culture fluid extract, which contains a high content of peptides and can promote skin improvement by maintaining clear and transparent skin. The purpose is to provide a cosmetic composition and a method for producing the same.
상기 과제를 해결하기 위한 본 발명의 실시예에 따른 인체지방세포배양액 추출물을 함유한 화장료 조성물은 인체지방세포배양액 추출물 5 ~ 15 중량%; 유화제 1 ~ 10 중량%; 계면활성제 0.1 ~ 6.0 중량%; 히알루론산 0.5 ~ 7 중량%; 펩타이드 0.01 ~ 5 중량%: 세라마이드 1 ~ 10 중량%; 알로에베라잎즙 0.1 ~ 7.0 중량%; 나이아신아마이드 0.5 ~ 5 중량%; 아데노신 0.1 ~ 5.0 중량%; 스쿠알란 5 ~ 40 중량%; 및 나머지 잔량의 정제수;를 포함하는 것을 특징으로 한다.A cosmetic composition containing a human fat cell culture fluid extract according to an embodiment of the present invention to solve the above problems includes 5 to 15% by weight of the human fat cell culture fluid extract; 1 to 10% by weight of emulsifier; Surfactant 0.1 to 6.0% by weight; Hyaluronic acid 0.5 to 7% by weight; Peptide 0.01 to 5% by weight: Ceramide 1 to 10% by weight; Aloe vera leaf juice 0.1 to 7.0% by weight; Niacinamide 0.5 to 5% by weight; Adenosine 0.1 to 5.0% by weight; 5 to 40% by weight of squalane; and the remaining amount of purified water.
상기 펩타이드는 카퍼펩타이드-1(Copper Tripeptide-1), 팔미토일트리펩타이드-1(Palmitoyl Tripeptide-1), 아세틸헥사펩타이드-8, 에스에이치-올리고펩타이드-1 및 알에이치-올리고펩타이드-2 중 선택된 1종 이상을 포함한다.The peptide is one selected from Copper Tripeptide-1, Palmitoyl Tripeptide-1, Acetylhexapeptide-8, SH-Oligopeptide-1, and RH-Oligopeptide-2. Includes more than one species.
상기 세라마이드 및 스쿠알란 각각은 고압 유화기를 통과시키는 고압 유화 처리에 의해, 나노입자 사이즈로 미립자화되어, 10 ~ 100nm의 평균 입경을 갖는다.Each of the ceramide and squalane is micronized into nanoparticles by high-pressure emulsification treatment through a high-pressure emulsifier, and has an average particle diameter of 10 to 100 nm.
상기 화장료 조성물은 pH 조절제 0.1 ~ 5 중량%; 유화 안정화제 0.01 ~ 5 중량%; 방부제 0.01 ~ 3 중량%; 및 향료 0.1 ~ 2 중량%; 중 1종 이상을 더 포함한다.The cosmetic composition contains 0.1 to 5% by weight of a pH adjuster; Emulsion stabilizer 0.01 to 5% by weight; Preservative 0.01 to 3% by weight; and 0.1 to 2% by weight of fragrance; Includes one or more of the following.
상기 과제를 해결하기 위한 본 발명의 실시예에 따른 인체지방세포배양액 추출물을 함유한 화장료 조성물 제조 방법은 (a) 수상의 화장료 원료를 계량 및 혼합하고 교반하면서 1차 가열하여 1차 혼합물을 형성하는 단계; (b) 세라마이드 및 스쿠알란을 고압 유화기를 통과시키는 고압 유화를 실시한 후, 냉각하여 나노입자 사이즈로 미립자화된 세라마이드 및 스쿠알란을 수득하는 단계; (c) 상기 나노입자 사이즈로 미립자화된 세라마이드 및 스쿠알란을 인체지방줄기세포배양액 추출물을 포함하는 유상의 화장료 원료에 혼합하고 교반하면서 2차 가열하여 2차 혼합물을 형성하는 단계; 및 (d) 상기 1차 혼합물에 2차 혼합물을 혼합하고 교반한 후, 냉각하여 화장료 조성물을 형성하는 단계;를 포함하며, 상기 (d) 단계 이후, 상기 화장료 조성물은 인체지방세포배양액 추출물 5 ~ 15 중량%, 유화제 1 ~ 10 중량%, 계면활성제 0.1 ~ 6.0 중량%, 히알루론산 0.5 ~ 7 중량%, 펩타이드 0.01 ~ 5 중량%, 세라마이드 1 ~ 10 중량%, 알로에베라잎즙 0.1 ~ 7.0 중량%, 나이아신아마이드 0.5 ~ 5 중량%, 아데노신 0.1 ~ 5.0 중량%, 스쿠알란 5 ~ 40 중량% 및 나머지 잔량의 정제수를 포함하는 것을 특징으로 한다.The method for producing a cosmetic composition containing human fat cell culture fluid extract according to an embodiment of the present invention to solve the above problem is (a) measuring and mixing the cosmetic raw materials in the water phase and performing primary heating while stirring to form a primary mixture. step; (b) performing high-pressure emulsification of ceramide and squalane through a high-pressure emulsifier, followed by cooling to obtain ceramide and squalane finely divided into nanoparticles; (c) mixing the ceramide and squalane micronized to the nanoparticle size with oily cosmetic raw materials containing human adipose stem cell culture fluid extract and secondary heating while stirring to form a secondary mixture; and (d) mixing the secondary mixture with the primary mixture, stirring the mixture, and then cooling to form a cosmetic composition. After step (d), the cosmetic composition is prepared from the human fat cell culture fluid extract 5 to 5. 15% by weight, emulsifier 1 to 10% by weight, surfactant 0.1 to 6.0% by weight, hyaluronic acid 0.5 to 7% by weight, peptide 0.01 to 5% by weight, ceramide 1 to 10% by weight, aloe vera leaf juice 0.1 to 7.0% by weight, It is characterized in that it contains 0.5 to 5% by weight of niacinamide, 0.1 to 5.0% by weight of adenosine, 5 to 40% by weight of squalane, and the remaining amount of purified water.
상기 (b) 단계에서, 상기 고압 유화는 50 ~ 80℃ 조건에서 700 ~ 2,500bar의 압력으로 실시한다.In step (b), the high-pressure emulsification is performed at a pressure of 700 to 2,500 bar under conditions of 50 to 80°C.
상기 (b) 단계에서, 상기 나노입자 사이즈로 미립자화된 세라미이드 및 스쿠알란 각각은 10 ~ 100nm의 평균 입경을 갖는다.In step (b), each of the ceramide and squalane micronized to the nanoparticle size has an average particle diameter of 10 to 100 nm.
본 발명에 따른 인체지방세포배양액 추출물을 함유한 화장료 조성물 및 그 제조 방법은 인체 지방조직에서 유래한 줄기세포 배양액인 인체지방세포배양액 추출물과 펩타이드가 고함량으로 함유되어 맑고 투명한 피부로 유지시켜 피부 개선 효과를 도모할 수 있다.The cosmetic composition containing human adipocyte culture fluid extract and its manufacturing method according to the present invention contains a high content of human adipocyte culture fluid extract, which is a stem cell culture fluid derived from human adipose tissue, and peptides, and improves skin by maintaining clear and transparent skin. effect can be achieved.
아울러, 본 발명에 따른 인체지방세포배양액 추출물을 함유한 화장료 조성물 및 그 제조 방법은 고압 유화 처리에 의해, 나노입자 사이즈로 미립자화된 세라마이드 및 스쿠알란에 의해 피부 깊숙이 빠르게 흡수되어 보습과 피부장벽 개선에 도움을 주어 건강한 피부를 만들어 줄 수 있을 뿐만 아니라, 나이아신아마이드와 아데노신이 함유되어 미백 및 주름개선에 탁월한 효과를 발휘한다.In addition, the cosmetic composition containing the human fat cell culture fluid extract according to the present invention and its manufacturing method are quickly absorbed deep into the skin by ceramide and squalane micronized into nanoparticle sizes through high-pressure emulsification treatment, helping to moisturize and improve the skin barrier. Not only can it create healthy skin, but it also contains niacinamide and adenosine, which are excellent for whitening and wrinkle improvement.
또한, 본 발명에 따른 인체지방세포배양액 추출물을 함유한 화장료 조성물 및 그 제조 방법은 히알루론산과 알로에베라잎즙이 유효 성분으로 함유되어, 피부 보습 및 진정 효과를 갖는다.In addition, the cosmetic composition containing human fat cell culture fluid extract and its manufacturing method according to the present invention contain hyaluronic acid and aloe vera leaf juice as active ingredients, and have a skin moisturizing and soothing effect.
도 1은 본 발명의 실시예에 따른 인체지방세포배양액 추출물을 함유한 화장료 조성물 제조 방법을 나타낸 공정 순서도.Figure 1 is a process flow chart showing a method for manufacturing a cosmetic composition containing a human fat cell culture fluid extract according to an embodiment of the present invention.
이하, 본 발명의 실시예에 대하여 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자가 용이하게 실시할 수 있도록 상세히 설명한다. 본 발명은 여러 가지 상이한 형태로 구현될 수 있으며 여기에서 설명하는 실시예에 한정되지 않는다. 이하 본 발명에 따른 인체지방세포배양액 추출물을 함유한 화장료 조성물 및 그 제조 방법을 첨부된 도면을 참고로 하여 상세히 기술되는 실시예들에 의해 그 특징들을 이해할 수 있을 것이다.Hereinafter, embodiments of the present invention will be described in detail so that those skilled in the art can easily implement the present invention. The present invention may be implemented in many different forms and is not limited to the embodiments described herein. Hereinafter, the features of the cosmetic composition containing the human fat cell culture fluid extract according to the present invention and its manufacturing method will be described in detail with reference to the attached drawings.
본 발명의 실시예에 따른 인체지방세포배양액 추출물을 함유한 화장료 조성물은 인체 지방조직에서 유래한 줄기세포 배양액인 인체지방세포배양액 추출물과 펩타이드가 고함량으로 함유되어 맑고 투명한 피부로 유지시켜 피부 개선 효과를 도모할 수 있다.The cosmetic composition containing human fat cell culture fluid extract according to an embodiment of the present invention contains a high content of human fat cell culture fluid extract and peptide, which is a stem cell culture fluid derived from human fat tissue, and has a skin improvement effect by maintaining clear and transparent skin. can be promoted.
아울러, 본 발명의 실시예에 따른 인체지방세포배양액 추출물을 함유한 화장료 조성물은 고압 유화 처리에 의해, 나노입자 사이즈로 미립자화된 세라마이드 및 스쿠알란에 의해 피부 깊숙이 빠르게 흡수되어 보습과 피부장벽 개선에 도움을 주어 건강한 피부를 만들어 줄 수 있을 뿐만 아니라, 나이아신아마이드와 아데노신이 함유되어 미백 및 주름개선에 탁월한 효과를 발휘한다.In addition, the cosmetic composition containing the extract of human fat cell culture fluid according to an embodiment of the present invention is quickly absorbed deep into the skin by ceramide and squalane micronized into nanoparticles by high-pressure emulsification treatment, helping to moisturize and improve the skin barrier. Not only can it create healthy skin, but it also contains niacinamide and adenosine, which are excellent for whitening and wrinkle improvement.
또한, 본 발명의 실시예에 따른 인체지방세포배양액 추출물을 함유한 화장료 조성물은 히알루론산과 알로에베라잎즙이 유효 성분으로 함유되어, 피부 보습 및 진정 효과를 갖는다.In addition, the cosmetic composition containing human fat cell culture fluid extract according to an embodiment of the present invention contains hyaluronic acid and aloe vera leaf juice as active ingredients, and has a skin moisturizing and soothing effect.
이를 위해, 본 발명의 실시예에 따른 인체지방세포배양액 추출물을 함유한 화장료 조성물은 인체지방세포배양액 추출물 5 ~ 15 중량%, 유화제 1 ~ 10 중량%, 계면활성제 0.1 ~ 6.0 중량%, 히알루론산 0.5 ~ 7 중량%, 펩타이드 0.01 ~ 5 중량%, 세라마이드 1 ~ 10 중량%, 알로에베라잎즙 0.1 ~ 7.0 중량%, 나이아신아마이드 0.5 ~ 5 중량%, 아데노신 0.1 ~ 5.0 중량%, 스쿠알란 5 ~ 40 중량% 및 나머지 잔량의 정제수를 포함한다.For this purpose, the cosmetic composition containing the human fat cell culture fluid extract according to an embodiment of the present invention contains 5 to 15% by weight of human fat cell culture fluid extract, 1 to 10% by weight of emulsifier, 0.1 to 6.0% by weight of surfactant, and 0.5% by weight of hyaluronic acid. ~ 7% by weight, peptide 0.01 ~ 5% by weight, ceramide 1 ~ 10% by weight, aloe vera leaf juice 0.1 ~ 7.0% by weight, niacinamide 0.5 ~ 5% by weight, adenosine 0.1 ~ 5.0% by weight, squalane 5 ~ 40% by weight, and Includes the remaining amount of purified water.
인체지방세포배양액 추출물은 인체 지방조직에서 유래한 줄기세포 배양액 및 배양한 지방줄기세포를 파쇄하여 얻을 수 있는 모든 추출물을 포함한다.Human fat cell culture fluid extract includes stem cell culture fluid derived from human adipose tissue and all extracts that can be obtained by disrupting cultured adipose stem cells.
인체 지방조직에서 유래한 줄기세포는 배아줄기세포를 제외한 성체로부터 얻어지는 줄기세포를 의미하며, 골수, 재대혈 및 말초혈액을 포함하는 혈액 및 지방조직의 기저에서 기원되는 줄기세포를 모두 포함하며, 반드시 이에 제한되는 것은 아니다.Stem cells derived from human adipose tissue refer to stem cells obtained from adult organisms excluding embryonic stem cells, and include all stem cells originating from the base of blood and adipose tissue, including bone marrow, uterine blood, and peripheral blood. It is not limited to this.
이러한 인체지방세포배양액 추출물의 유효 성분은 주로 세포의 성장을 조절하는 펩타이드와 단백질로서, 예를 들면 PDGF(혈소판 유래 성장인자), Basic FGF(염기성 섬유아세포 성장인자), KGF(각질세포 성장인자), TGF-β1(형질변환성장인자), HGF(간세포 성장인자), VEGF(혈관내피 성장인자), 콜라겐, 파이브로넥틴, SOD(항산화효소) 등을 포함하며, 이에 제한되지 않는다. 인체지방세포배양액 추출물은 상기한 성장인자를 함유하고 있기 때문에 피부 구성세포인 섬유아세포 이동 촉진, 활성화 효과, 피부 재생 및 항노화 효과, 콜라겐합성 증가, 티로시나제의 활성 억제 효과, 멜라닌 합성 억제, 모발 성장 및 축소된 모낭 복원 효과를 기대할 수 있다.The active ingredients of this human fat cell culture fluid extract are mainly peptides and proteins that regulate cell growth, such as PDGF (platelet-derived growth factor), Basic FGF (basic fibroblast growth factor), and KGF (keratinocyte growth factor). , TGF-β1 (transforming growth factor), HGF (hepatocyte growth factor), VEGF (vascular endothelial growth factor), collagen, fibronectin, SOD (antioxidant enzyme), etc., but are not limited thereto. Since the human fat cell culture fluid extract contains the above-mentioned growth factors, it promotes the migration of fibroblasts, which are skin constituent cells, has an activation effect, has a skin regeneration and anti-aging effect, increases collagen synthesis, has an inhibitory effect on the activity of tyrosinase, inhibits melanin synthesis, and has hair growth effects. and the effect of restoring reduced hair follicles can be expected.
따라서, 인체지방세포배양액 추출물은 맑고 투명한 피부로 가꾸어 주는데 탁월한 효과를 발휘한다.Therefore, human fat cell culture fluid extract has an excellent effect in creating clear and transparent skin.
이러한 인체지방세포배양액 추출물은 화장료 조성물 전체 중량의 5 ~ 15 중량%의 고함량으로 첨가되는 것이 바람직하고, 보다 바람직하게는 6 ~ 9 중량%의 함량비로 첨가되는 것이 좋다. 인체지방세포배양액 추출물의 첨가량이 5 중량% 미만일 경우에는 그 첨가량이 낮아 맑고 투명한 피부를 유지시키는데 어려움이 따를 수 있고, 인체지방세포배양액 추출물의 첨가량이 15 중량%를 초과하여 다량 첨가될 경우에는 제형 안정성을 저하시킬 우려가 있으므로, 바람직하지 못하다.This human fat cell culture fluid extract is preferably added at a high content of 5 to 15% by weight of the total weight of the cosmetic composition, and more preferably at a content ratio of 6 to 9% by weight. If the amount of human fat cell culture fluid extract added is less than 5% by weight, it may be difficult to maintain clear and transparent skin due to the low amount, and if the amount of human fat cell culture fluid extract is added in excess of 15% by weight, the formulation It is undesirable because there is a risk of lowering stability.
유화제는 높은 사용감 및 유화 안정성을 유지하는 역할을 한다. 이러한 유화제는 화장료 조성물 전체 중량의 1 ~ 10 중량%의 함량비로 첨가되는 것이 바람직하고, 보다 바람직하게는 3 ~ 7 중량%의 함량비로 첨가되는 것이 좋다.Emulsifiers play a role in maintaining a high feeling of use and emulsion stability. These emulsifiers are preferably added at an amount of 1 to 10% by weight of the total weight of the cosmetic composition, and more preferably at an amount of 3 to 7% by weight.
이러한 유화제는 글리세릴 스테아레이트(Glyceryl Stearate), 세테아레스-20(Ceteareth-20), 세테라레스-12(Ceteareth-12), 세테아릴알코올(Cetearyl Alcohol), 세틸팔미테이트(Cetyl Palmitate), 글리세릴 스테아레이트(Glyceryl Stearate), PEG-100 스테아레이트(PEG-100 Stearate), 폴리하이드록시스테아릭산(Polyhydroxystearic Acid), 레시틴(Lecithin), 에틸헥실팔미네이트(Ethylhexyl Palmitate), 이소프로필 미리스테이트(Isopropyl Myristate), 아이소스테아르산(Isostearic Acid), 폴리글리세릴-3 폴리리시놀리에이트(Polyglyceryl-3 Polyricinoleate), 라우릴 PEG-9 폴리다이메틸실록시에틸다이메티콘(Lauryl PEG-9 Polydimethylsiloxyethyl Dimethicone) 및 PEG-10 다이메티콘(PEG-10 Dimethicone) 중 선택된 1종 이상을 포함할 수 있다.These emulsifiers include Glyceryl Stearate, Ceteareth-20, Ceteareth-12, Cetearyl Alcohol, Cetyl Palmitate, Glyceryl Stearate, PEG-100 Stearate, Polyhydroxystearic Acid, Lecithin, Ethylhexyl Palmitate, Isopropyl Myristate ( Isopropyl Myristate, Isostearic Acid, Polyglyceryl-3 Polyricinoleate, Lauryl PEG-9 Polydimethylsiloxyethyl Dimethicone and PEG-10 Dimethicone.
계면활성제는 소듐스테아로일 글루타메이트(Sodium Stearoyl Glutamate), 소듐라우릴글루타메이드(Sodium Lauryl Glutamate), 포타슘세틸포스페이트(Potassium Cetyl Phosphate), 글리세릴스테아레 이트시트레이트(Glyceryl Stearate Citrate) 및 디스테아릴디모늄클로라이드(Distearyl Dimonium Chloride) 중 선택된 1종 이상을 포함할 수 있다.Surfactants are Sodium Stearoyl Glutamate, Sodium Lauryl Glutamate, Potassium Cetyl Phosphate, Glyceryl Stearate Citrate and Distear. It may include one or more selected from Distearyl Dimonium Chloride.
이러한 계면활성제는 화장료 조성물 전체 중량의 0.1 ~ 6.0 중량%의 함량비로 첨가되는 것이 바람직하고, 보다 바람직하게는 1.5 ~ 4.5 중량%의 함량비로 첨가되는 것이 좋다. 계면활성제의 첨가량이 0.1 중량% 미만일 경우에는 제형으로 적용시 안정화 효과가 미미하여 입자형성이 이루어지지 않을 수 있고, 계면활성제의 첨가량이 6.0 중량%를 초하여 과다 첨가될 시에는 피부에 자극이 발생시킬 우려가 있다.These surfactants are preferably added at an amount of 0.1 to 6.0% by weight of the total weight of the cosmetic composition, and more preferably at an amount of 1.5 to 4.5% by weight. If the amount of surfactant added is less than 0.1% by weight, the stabilizing effect when applied to the formulation may be minimal and particle formation may not occur, and if the amount of surfactant added exceeds 6.0% by weight, it may cause skin irritation. There are concerns.
히알루론산은 주름개선 및 노화방지의 기능을 갖는 대표적인 물질이다. 이러한 히알루론산은 피부의 속과 겉에서 보습막을 형성하여 피부에 수분을 공급하여 촉촉한 피부를 유지시키는 역할을 하다.Hyaluronic acid is a representative substance that has anti-wrinkle and anti-aging functions. This hyaluronic acid forms a moisturizing film on the inside and outside of the skin and supplies moisture to the skin to keep the skin moist.
히알루론산은 화장료 조성물 전체 중량의 0.5 ~ 7 중량%의 함량비로 첨가되는 것이 바람직하고, 보다 바람직하게는 2 ~ 5 중량%의 함량비로 첨가되는 것이 좋다. 히알루론산의 첨가량이 0.5 중량% 미만일 경우에는 상기의 효과를 제대로 발휘하는데 어려움이 따를 수 있고, 히알루론산의 첨가량이 7 중량%를 초과하여 과다 첨가될 경우에는 제형 안정성을 저하시킬 우려가 있으므로, 바람직하지 못하다.Hyaluronic acid is preferably added at an amount of 0.5 to 7% by weight of the total weight of the cosmetic composition, and more preferably at an amount of 2 to 5% by weight. If the amount of hyaluronic acid added is less than 0.5% by weight, it may be difficult to properly exert the above effect, and if the amount of hyaluronic acid added exceeds 7% by weight, there is a risk of reducing the formulation stability, so it is preferable. can't do it
펩타이드는 화장료 조성물에 유효성분으로 첨가된다. 이러한 펩타이드는 피부재생능력이 뛰어나 상처의 치유를 촉진하고, 피부의 탄력을 강화하며, 피하지방층을 증가시켜 피부의 노화현상을 막아준다.Peptides are added as active ingredients to cosmetic compositions. These peptides have excellent skin regenerative abilities, promoting wound healing, strengthening skin elasticity, and increasing the subcutaneous fat layer to prevent skin aging.
이러한 펩타이드는 카퍼펩타이드-1(Copper Tripeptide-1), 팔미토일트리펩타이드-1(Palmitoyl Tripeptide-1), 아세틸헥사펩타이드-8, 에스에이치-올리고펩타이드-1 및 알에이치-올리고펩타이드-2 중 선택된 1종 이상을 포함한다.These peptides are selected from Copper Tripeptide-1, Palmitoyl Tripeptide-1, Acetylhexapeptide-8, SH-Oligopeptide-1, and RH-Oligopeptide-2. Includes more than one species.
펩타이드는 화장료 조성물 전체 중량의 0.01 ~ 5 중량%의 함량비로 첨가되는 것이 바람직하고, 보다 바람직하게는 1 ~ 3 중량%의 ◎량비로 첨가되는 것이 좋다. 펩타이드의 첨가량이 0.01 중량% 미만일 경우에는 그 첨가량이 미미하여 상기의 효과를 제대로 발휘하기 어렵고, 펩타이드의 첨가량이 5 중량%를 초과하여 과다 첨가될 경우에는 점도 형성이 약하여 제형화가 어려울 수 있다.The peptide is preferably added in an amount of 0.01 to 5% by weight of the total weight of the cosmetic composition, and more preferably in an amount of 1 to 3% by weight. If the amount of peptide added is less than 0.01% by weight, the amount added is so small that it is difficult to properly exert the above effect, and if the amount of peptide added exceeds 5% by weight, viscosity formation is weak and formulation may be difficult.
세라마이드는 피부 친화성 및 강한 보습작용으로 인하여 피부장벽 기능을 회복시켜 피부장벽 개선에 도움을 준다. 일반적으로, 세라마이드는 입체 화학적 구조 및 소수성 등으로 물과 오일 모두에 있어 용해도가 매우 낮아 고함량을 화장품 제형에 적용하는데 한계가 있었나, 본 발명에서는 초고압으로 유지되는 고압 유화기를 통과시키는 고압 유화 처리를 적용하는 것에 의해, 세라마이드를 나노입자 사이즈로 미립자화하여 안정화시켰다. 이에 따라, 세라마이드는 100nm 이하의 평균 입경, 보다 바람직하게는 10 ~ 100nm의 평균 입경을 갖는 나노입자 사이즈를 갖는다.Ceramide helps improve the skin barrier by restoring skin barrier function due to its skin affinity and strong moisturizing effect. In general, ceramide has a very low solubility in both water and oil due to its stereochemical structure and hydrophobicity, which limits the application of high amounts in cosmetic formulations. However, in the present invention, high pressure emulsification treatment is performed by passing it through a high pressure emulsifier maintained at ultra-high pressure. By application, ceramide was miniaturized into nanoparticle size and stabilized. Accordingly, ceramide has a nanoparticle size with an average particle size of 100 nm or less, more preferably 10 to 100 nm.
세라마이드는 화장료 조성물 전체 중량의 1 ~ 10 중량%의 함량비로 첨가되는 것이 바람직하고, 보다 바람직하게는 3 ~ 7 중량%의 함량비로 첨가되는 것이 좋다. 세라마이드의 첨가량이 1 중량% 미만일 경우에는 피부장벽 개선 효과를 제대로 발휘하기 어려울 수 있고, 세라마이드 첨가량이 10 중량%를 초과하여 과다 첨가될 경우에는 점도 형성이 약하여 제형화가 어려울 수 있다.Ceramide is preferably added at an amount of 1 to 10% by weight of the total weight of the cosmetic composition, and more preferably at an amount of 3 to 7% by weight. If the amount of ceramide added is less than 1% by weight, it may be difficult to properly demonstrate the skin barrier improvement effect, and if the amount of ceramide added exceeds 10% by weight, formulation may be difficult due to poor viscosity formation.
알로에베라잎즙은 피부 보습 및 피부 진정에 도움을 주는 유효성분으로 첨가된다. 이러한 알로에베라잎즙은 화장료 조성물 전체 중량의 0.1 ~ 7.0 중량% 중량%의 함량비로 첨가되는 것이 바람직하고, 보다 바람직하게는 3 ~ 5 중량%의 함량비로 첨가되는 것이 좋다.Aloe vera leaf juice is added as an active ingredient that helps moisturize and soothe the skin. This aloe vera leaf juice is preferably added at a content ratio of 0.1 to 7.0% by weight of the total weight of the cosmetic composition, and more preferably at a content ratio of 3 to 5% by weight.
알로에베라잎즙의 첨가량이 0.1 중량% 미만일 경우에는 그 첨가량이 미미하여 피부 보습 및 피부 진정 효과를 제대로 발휘하기 어렵고, 알로에베라잎즙의 첨가량이 7 중량%를 초과하여 다량 첨가될 경우에는 화장료 조성물의 점도가 높아져 끈적임이 발생할 수 있으므로, 바람직하지 못하다.If the amount of aloe vera leaf juice added is less than 0.1% by weight, the amount added is so small that it is difficult to properly exert the skin moisturizing and skin soothing effect. If the added amount of aloe vera leaf juice exceeds 7% by weight, the viscosity of the cosmetic composition may decrease. It is undesirable because it may increase and cause stickiness.
나이아신아마이드는 강한 보습 효과로 피부 미백 및 주름개선에 탁월한 효능을 발휘한다. 이러한 나이아신아마이드는 화장료 조성물 전체 중량의 0.5 ~ 5 중량% 중량%의 함량비로 첨가되는 것이 바람직하고, 보다 바람직하게는 1.5 ~ 3.5 중량%의 함량비로 첨가되는 것이 좋다. 나이아신아마이드의 첨가량이 0.5 중량% 미만일 경우에는 그 첨가량이 미미하여 보습 효과를 제대로 발휘하지 못해 피부 미백 및 주름개선 효과를 제대로 발휘하기 어렵고, 나이아신아마이드의 첨가량이 5 중량%를 초과하여 다량 첨가될 경우에는 화장료 조성물의 점도가 높아져 끈적임이 발생할 수 있으므로, 바람직하지 못하다.Niacinamide has a strong moisturizing effect and is excellent for skin whitening and wrinkle improvement. Such niacinamide is preferably added at a content ratio of 0.5 to 5% by weight of the total weight of the cosmetic composition, and more preferably at a content ratio of 1.5 to 3.5% by weight. If the amount of niacinamide added is less than 0.5% by weight, the amount added is so small that the moisturizing effect cannot be properly achieved, making it difficult to properly achieve the skin whitening and wrinkle improvement effects. If the amount of niacinamide is added in excess of 5% by weight, it is difficult to achieve the moisturizing effect properly. This is undesirable because the viscosity of the cosmetic composition may increase and stickiness may occur.
아데노신은, 나이아신아마이드와 함께 첨가되어, 강한 보습 효과로 피부 미백 및 주름개선에 탁월한 효능을 발휘한다. 이러한 아데노신은 화장료 조성물 전체 중량의 0.1 ~ 5.0 중량%의 함량비로 첨가되는 것이 바람직하고, 보다 바람직하게는 2 ~ 4 중량%의 함량비로 첨가되는 것이 좋다.Adenosine is added together with niacinamide and has a strong moisturizing effect, making it excellent for skin whitening and wrinkle improvement. Such adenosine is preferably added in an amount of 0.1 to 5.0% by weight of the total weight of the cosmetic composition, and more preferably in an amount of 2 to 4% by weight.
아데노신의 첨가량이 0.1 중량% 미만일 경우에는 그 첨가량이 미미하여 보습 효과를 제대로 발휘하지 못해 피부 미백 및 주름개선 효과를 제대로 발휘하기 어렵고, 아데노신의 첨가량이 5.0 중량%를 초과하여 다량 첨가될 경우에는 화장료 조성물의 점도가 높아져 끈적임이 발생할 수 있으므로, 바람직하지 못하다.If the amount of adenosine added is less than 0.1% by weight, the amount added is so small that the moisturizing effect cannot be properly demonstrated, making it difficult to properly demonstrate the skin whitening and wrinkle improvement effects. If the amount of adenosine added exceeds 5.0% by weight, the cosmetic composition This is undesirable because the viscosity may increase and stickiness may occur.
스쿠알란은 피부 보습 및 피부장벽 개선에 유효한 성분이다. 본 발명에서, 스쿠알란은 세라마이드와 함께 초고압으로 유지되는 고압 유화기를 통과시키는 고압 유화 처리가 이루어지는 것에 의해, 나노입자 사이즈로 미립자화하여 안정화시켰다. 이에 따라, 스쿠알란은 100nm 이하의 평균 입경, 보다 바람직하게는 10 ~ 100nm의 평균 입경을 갖는 나노입자 사이즈를 갖는다.Squalane is an effective ingredient for moisturizing the skin and improving the skin barrier. In the present invention, squalane was stabilized by being miniaturized into nanoparticles in size by performing a high-pressure emulsification treatment by passing it through a high-pressure emulsifier maintained at ultra-high pressure together with ceramide. Accordingly, squalane has a nanoparticle size with an average particle diameter of 100 nm or less, more preferably 10 to 100 nm.
스쿠알란은 화장료 조성물 전체 중량의 5 ~ 40 중량% 중량%의 함량비로 첨가되는 것이 바람직하고, 보다 바람직하게는 10 ~ 25 중량%의 함량비로 첨가되는 것이 좋다. 스쿠알란의 첨가량이 5 중량% 미만일 경우에는 피부 보습 및 피부장벽 개선 효과를 제대로 발휘하기 어렵고, 스쿠알란의 첨가량이 40 중량%를 초과하여 과다 첨가될 경우에는 점도 형성이 약하여 제형화가 어려울 수 있다.Squalane is preferably added at a content ratio of 5 to 40% by weight of the total weight of the cosmetic composition, and more preferably at a content ratio of 10 to 25% by weight. If the amount of squalane added is less than 5% by weight, it is difficult to properly exert the skin moisturizing and skin barrier improvement effect, and if the amount of squalane added exceeds 40% by weight, the viscosity formation is weak and formulation may be difficult.
또한, 본 발명의 실시예에 따른 인체지방세포배양액 추출물을 함유한 화장료 조성물은 pH 조절제 0.1 ~ 5 중량%, 유화 안정화제 0.01 ~ 5 중량%, 방부제 0.01 ~ 3 중량%, 향료 0.1 ~ 2 중량% 및 N,N'－p－페닐렌비스말레이미드 0.1 ~ 2.0 중량% 중 1종 이상을 더 포함할 수 있다.In addition, the cosmetic composition containing the human fat cell culture fluid extract according to an embodiment of the present invention contains 0.1 to 5% by weight of a pH adjuster, 0.01 to 5% by weight of an emulsion stabilizer, 0.01 to 3% by weight of a preservative, and 0.1 to 2% by weight of fragrance. and 0.1 to 2.0% by weight of N,N'-p-phenylenebismaleimide.
pH 조절제는 화장료 조성물 내에 첨가되어 pH를 조절하는 역할을 한다. 이러한 pH 조절제는 KOH, NaOH, 테트라에틸암모늄, 알지네이트 등에서 선택된 1종 이상을 포함할 수 있으나, 이에 제한되는 것은 아니다.The pH adjuster is added to the cosmetic composition and plays a role in controlling pH. These pH adjusters may include one or more selected from KOH, NaOH, tetraethylammonium, alginate, etc., but are not limited thereto.
이러한 pH 조절제는 화장료 조성물 전체 중량의 0.1 ~ 5 중량%의 함량비로 첨가되는 것이 바람직하고, 2 ~ 4 중량%의 함량비로 첨가되는 것이 보다 바람직하다. pH 조절제의 첨가량이 0.1 중량% 미만일 경우에는 그 첨가량이 미미하여 화장료 조성물의 pH 값을 조절하기 어려울 수 있고, pH 조절제의 첨가량이 5 중량%를 초과하여 다량 첨가될 경우에는 제형 안정성 확보에 어려움이 따를 수 있다.This pH adjuster is preferably added in an amount of 0.1 to 5% by weight, and more preferably in an amount of 2 to 4% by weight of the total weight of the cosmetic composition. If the added amount of the pH adjuster is less than 0.1% by weight, the added amount is so small that it may be difficult to control the pH value of the cosmetic composition, and if the added amount of the pH adjuster exceeds 5% by weight, it may be difficult to ensure formulation stability. You can.
유화 안정화제는 유화제의 유화력을 보조하기 위해 첨가된다. 이러한 유화 안정화제는 화장료 조성물 전체 중량의 0.01 ~ 5 중량%의 함량비로 첨가될 수 있으나, 이에 제한되는 것은 아니다.Emulsion stabilizers are added to assist the emulsifying power of the emulsifier. This emulsion stabilizer may be added in an amount of 0.01 to 5% by weight of the total weight of the cosmetic composition, but is not limited thereto.
유화 안정화제는 하이드로제네이티드 레시틴(Hydrogenated Lecithin), 이눌린 라우릴 카바메이트(Inulin Lauryl Carbamate), 트리메틸실록시실리케이트(Trimethylsiloxysilicate), 사이클로펜타실록세인(Cyclopentasiloxane), 아크릴레이트/스테아릴 아크릴레이트/다이메티콘 메타크릴레이트 공중합체(Acrylates/Stearyl Acrylate/Dimethicone Methacrylate Copolymer) 및 다이카프릴 카보네이트(Dicaprylyl Carbonate) 중 선택된 1종 이상을 포함할 수 있으나, 이에 제한되는 것은 아니다.Emulsion stabilizers include Hydrogenated Lecithin, Inulin Lauryl Carbamate, Trimethylsiloxysilicate, Cyclopentasiloxane, Acrylate/Stearyl Acrylate/Dime. It may include one or more selected from Acrylates/Stearyl Acrylate/Dimethicone Methacrylate Copolymer and Dicaprylyl Carbonate, but is not limited thereto.
방부제는 나노에멀젼에 첨가되는 상의 안정을 위해 첨가되는 물질로서, 화장료 제형의 보존기간을 증가시키는 역할을 한다. 방부제는 나노에멀젼 전체 중량의 0.01 ~ 3 중량%의 함량비로 첨가될 수 있으나, 이에 제한되는 것은 아니다.Preservatives are substances added to stabilize the phase added to nanoemulsions and serve to increase the shelf life of cosmetic formulations. The preservative may be added in an amount of 0.01 to 3% by weight of the total weight of the nanoemulsion, but is not limited thereto.
이러한 방부제는 1,2-헥산다이올(1,2-Hexanediol), 에틸헥실글리세린(Ethylhexylglycerin), 펜틸렌 글리콜(Pentylene Glycol) 중 선택된 1종 이상을 포함할 수 있으나, 이에 제한되는 것은 아니다.These preservatives may include, but are not limited to, one or more selected from 1,2-hexanediol, ethylhexylglycerin, and pentylene glycol.
향료는 화장료 조성물에 다양한 향을 부여하는 착향제로서의 역할을 한다. 이러한 향료는 해당 기술 분야에서 통상적으로 사용되는 것이라면 제한 없이 사용될 수 있다.Fragrances serve as flavoring agents that impart various scents to cosmetic compositions. These fragrances may be used without limitation as long as they are commonly used in the relevant technical field.
향료는 화장료 조성물 전체 중량의 0.1 ~ 2 중량%의 함량비로 첨가되는 것이 바람직하다. 향료의 첨가량이 0.1 중량% 미만일 경우에는 화장료 조성물을 사용자의 피부에 발라 사용할 시 향이 오랫동안 지속되지 못할 우려가 있고, 향료의 첨가량이 2 중량%를 초과하여 다량 첨가될 경우에는 더 이상의 효과 상승 없이 제조비용만을 증가시키는 요인으로 작용할 수 있으므로, 바람직하지 못하다.Fragrances are preferably added in an amount of 0.1 to 2% by weight of the total weight of the cosmetic composition. If the amount of fragrance added is less than 0.1% by weight, there is a risk that the fragrance may not last for a long time when the cosmetic composition is applied to the user's skin, and if the amount of fragrance added is more than 2% by weight, the effect is not increased any further. This is undesirable because it may act as a factor that only increases costs.
N,N'－p－페닐렌비스말레이미드는 제형 안정성 및 피부자극을 유발하지 않도록 보조하는 역할을 한다. 이러한 N,N'－p－페닐렌비스말레이미드는 화장료 조성물 전체 중량의 0.1 ~ 2.0 중량%의 함량비로 첨가되는 것이 바람직하다. N,N'－p－페닐렌비스말레이미드의 첨가량이 0.1 중량% 미만일 경우에는 상기의 효과를 제대로 발휘하기 어렵고, N,N'－p－페닐렌비스말레이미드의 첨가량이 2.0 중량%를 초과하여 다량 첨가될 경우에는 화장료 조성물의 점도가 높아져 사용감이 나빠질 수 있다.N,N'-p-phenylenebismaleimide helps maintain formulation stability and prevents skin irritation. This N,N'-p-phenylenebismaleimide is preferably added in an amount of 0.1 to 2.0% by weight of the total weight of the cosmetic composition. If the amount of N,N'-p-phenylenebismaleimide added is less than 0.1% by weight, it is difficult to properly achieve the above effect, and the amount of N,N'-p-phenylenebismaleimide added exceeds 2.0% by weight. Therefore, if a large amount is added, the viscosity of the cosmetic composition may increase and the feeling of use may worsen.
정제수는 유효성분을 용해시키기 위해 사용되며, 1차 이상의 증류를 거쳐 수득되거나, 필터를 통해 정제된 물일 수 있다.Purified water is used to dissolve the active ingredient, and may be obtained through one or more distillations, or may be water purified through a filter.
본 발명의 실시예에 따른 인체지방세포배양액 추출물을 함유한 화장료 조성물은 제형이 특별히 한정되지 않으며, 목적하는 바에 따라 적절히 선택할 수 있다. 예를 들어, 앰플, 스킨로션, 스킨소프너, 스킨토너, 아스트린젠트, 로션, 밀크로션, 모이스쳐 로션, 영양로션, 맛사지 크림, 영양 크림, 모이스처 크림, 핸드 크림, 파운데이션, 에센스, 영양 에센스, 클렌징 로션, 클렌징 크림, 바디 로션, 바디 클린저 등에서 선택된 어느 하나 이상의 제형으로 제조될 수 있으나, 이에 제한되는 것은 아니다.The formulation of the cosmetic composition containing the extract of human fat cell culture fluid according to an embodiment of the present invention is not particularly limited, and can be appropriately selected depending on the purpose. For example, ampoule, skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisture lotion, nutrition lotion, massage cream, nutrition cream, moisture cream, hand cream, foundation, essence, nutrition essence, cleansing lotion, It may be manufactured in one or more formulations selected from cleansing cream, body lotion, body cleanser, etc., but is not limited thereto.
이하에서는 본 발명의 실시예에 따른 인체지방세포배양액 추출물을 함유한 화장료 조성물 제조 방법에 대하여 설명하도록 한다.Hereinafter, a method for manufacturing a cosmetic composition containing human fat cell culture fluid extract according to an embodiment of the present invention will be described.
도 1은 본 발명의 실시예에 따른 인체지방세포배양액 추출물을 함유한 화장료 조성물 제조 방법을 나타낸 공정 순서도이다.Figure 1 is a process flow chart showing a method for manufacturing a cosmetic composition containing a human fat cell culture fluid extract according to an embodiment of the present invention.
도 1에 나타낸 바와 같이, 본 발명의 실시예에 따른 인체지방세포배양액 추출물을 함유한 화장료 조성물 제조 방법은 1차 혼합물 형성 단계(S110), 고압 유화 단계(S120), 2차 혼합물 형성 단계(S130) 및 화장료 조성물 형성 단계(S140)를 포함한다.As shown in Figure 1, the method for producing a cosmetic composition containing a human fat cell culture fluid extract according to an embodiment of the present invention includes a first mixture forming step (S110), a high pressure emulsification step (S120), and a second mixture forming step (S130). ) and a cosmetic composition forming step (S140).
1차 혼합물 형성Primary mixture formation
1차 혼합물 형성 단계(S110)에서는 수상의 화장료 원료를 계량 및 혼합하고 교반하면서 1차 가열하여 1차 혼합물을 형성한다.In the primary mixture forming step (S110), the cosmetic raw materials in the water phase are first heated while weighed, mixed, and stirred to form a primary mixture.
본 단계에서, 1차 가열 및 교반은 60 ~ 80℃ 조건에서 1,000 ~ 1,500rpm의 속도로 30 ~ 90분 동안 실시하는 것이 바람직하다. 1차 가열 온도가 60℃ 미만일 경우에는 수상의 화장료 원료가 정제수에 완전히 용해되지 못할 수 있고, 1차 가열 온도가 80℃를 초과할 경우에는 정제수가 기화될 염려가 있다. 또한, 교반 속도가 1,000rpm 미만이거나, 교반 시간이 30분 미만일 경우에는 수상의 화장료 원료가 정제수에 완전히 용해되지 못할 우려가 있고, 교반 속도가 1,500rpm을 초과하거나, 교반 시간이 90분을 초과할 경우에는 더 이상의 효과 없이 제조 비용만을 상승시키는 요인으로 작용할 수 있으므로, 경제적이지 못하다.In this step, the first heating and stirring is preferably performed at a temperature of 60 to 80°C and a speed of 1,000 to 1,500 rpm for 30 to 90 minutes. If the primary heating temperature is less than 60℃, the cosmetic raw materials in the water phase may not be completely dissolved in purified water, and if the primary heating temperature exceeds 80℃, there is a risk that the purified water may evaporate. In addition, if the stirring speed is less than 1,000 rpm or the stirring time is less than 30 minutes, there is a risk that the cosmetic raw materials in the water phase may not be completely dissolved in purified water. If the stirring speed exceeds 1,500 rpm or the stirring time exceeds 90 minutes, there is a risk that the cosmetic raw materials in the water phase will not be completely dissolved in the purified water. In this case, it can act as a factor that only increases manufacturing costs without any further effect, so it is not economical.
고압 유화high pressure oil painting
고압 유화 단계(S120)에서는 세라마이드 및 스쿠알란을 고압 유화기를 통과시키는 고압 유화를 실시한 후, 냉각하여 나노입자 사이즈로 미립자화된 세라마이드 및 스쿠알란을 수득한다.In the high-pressure emulsification step (S120), ceramide and squalane are subjected to high-pressure emulsification by passing them through a high-pressure emulsifier, and then cooled to obtain ceramide and squalane finely divided into nanoparticles.
본 단계에서, 세라마이드 및 스쿠알란 각각은 고압 유화기를 통과시키는 고압 유화 처리에 의해, 나노입자 사이즈로 미립자화되어, 100nm 이하의 평균 입경, 보다 바람직하게는 10 ~ 100nm의 평균 입경을 갖는 나노입자 사이즈를 갖는다.In this step, each of the ceramide and squalane is micronized into nanoparticles by high-pressure emulsification treatment through a high-pressure emulsifier, so that the nanoparticles have an average particle size of 100 nm or less, more preferably 10 to 100 nm. have
이를 위해, 고압 유화 단계(S120)에서는 세라마이드 및 스쿠알란을 50 ~ 80℃ 조건에서 700 ~ 2,500bar의 압력으로 유지되는 고압 유화기 내에 통과시킨 후, 10 ~ 40℃까지 냉각하여 나노입자 사이즈로 미립자화된 세라마이드 및 스쿠알란을 수득하였다.For this purpose, in the high-pressure emulsification step (S120), ceramide and squalane are passed through a high-pressure emulsifier maintained at a pressure of 700 to 2,500 bar under conditions of 50 to 80 ℃, and then cooled to 10 to 40 ℃ to micronize into nanoparticles. Ceramide and squalane were obtained.
이와 같이, 고압 유화기(Microfluidizer)에 의한 나노에멀젼 제형을 제조함에 있어서, 700 ~ 2,500bar의 고압을 가하고 이를 고속으로 변환하여 이 힘을 이용하여, 벌크 입자(Bulk particle)를 나노입자화로 유화하는 것이 가능해질 수 있다.In this way, in manufacturing a nanoemulsion formulation using a high-pressure emulsifier (microfluidizer), high pressure of 700 to 2,500 bar is applied, converted to high speed, and this force is used to emulsify bulk particles into nanoparticles. It could become possible.
이를 위해, 본 발명의 고압 유화기는 마이크로 단위의 직경을 가지는 입자를 700 ~ 2,500bar의 초고압으로 유지되는 반응 챔버에 강제 주입시켜, 반응 챔버 내에서 충돌, 전단력, 공동현상 등의 3가지 힘에 의하여 나노 크기를 갖는 입자 형성을 갖도록 제어한 것이다.For this purpose, the high-pressure emulsifier of the present invention forcibly injects particles with micro-scale diameters into a reaction chamber maintained at an ultra-high pressure of 700 to 2,500 bar, and causes them to be emitted by three forces such as collision, shear force, and cavitation within the reaction chamber. It was controlled to form nano-sized particles.
이러한 고압 유화 단계(S120)시, 세라마이드 및 스쿠알란은 고압 유화기 내에 1 ~ 6회, 보다 바람직하게는 2 ~ 4회 동안 반복해서 통과시키는 것이 바람직한데, 이는 고압 유화기의 반응 챔버 내에서 2 ~ 4회 동안 반복해서 통과시켜야 충돌, 전단력 및 공동현상을 보다 극대화할 수 있으므로, 나노입자 사이즈로 미립자화하는 것이 용이하여 안정화하는데 보다 유리하기 때문이다.During this high-pressure emulsification step (S120), it is preferable to pass the ceramide and squalane repeatedly through the high-pressure emulsifier 1 to 6 times, more preferably 2 to 4 times, which means 2 to 4 times in the reaction chamber of the high-pressure emulsifier. This is because collisions, shear force, and cavitation can be maximized by repeatedly passing the material four times, and it is easier to atomize it into nanoparticles, making it more advantageous for stabilization.
2차 혼합물 형성Secondary mixture formation
2차 혼합물 형성 단계(S130)에서는 나노입자 사이즈로 미립자화된 세라마이드 및 스쿠알란을 인체지방줄기세포배양액 추출물을 포함하는 유상의 화장료 원료에 혼합하고 교반하면서 2차 가열하여 2차 혼합물을 형성한다.In the secondary mixture forming step (S130), ceramide and squalane finely divided into nanoparticles are mixed with oily cosmetic raw materials containing human adipose stem cell culture fluid extract and secondary heating is performed while stirring to form a secondary mixture.
본 단계에서, 2차 가열 및 교반은 80 ~ 100℃ 조건에서 2,500 ~ 3,500rpm의 속도로 3 ~ 10시간 동안 실시하는 것이 바람직하다. 2차 가열 온도가 80℃ 미만일 경우에는 2차 혼합물 내의 각 성분들이 완전히 용해되기 어렵고, 2차 가열 온도가 100℃를 초과할 경우에는 과도한 에너지 사용으로 인해 제조비용을 상승시키는 문제를 유발할 수 있다.In this step, the secondary heating and stirring is preferably performed at a temperature of 80 to 100°C and a speed of 2,500 to 3,500 rpm for 3 to 10 hours. If the secondary heating temperature is less than 80°C, it is difficult for each component in the secondary mixture to completely dissolve, and if the secondary heating temperature exceeds 100°C, it may cause problems that increase manufacturing costs due to excessive energy use.
또한, 2차 교반 속도가 2,500rpm 미만이거나, 교반 시간이 3시간 미만일 경우에는 2차 혼합물 내의 각 성분들이 완전히 용해되지 못하여 분산성 확보에 어려움이 따를 수 있고, 교반 속도가 3,500rpm을 초과하거나, 교반 시간이 10시간을 초과할 경우에는 더 이상의 효과 없이 제조 비용만을 상승시키는 요인으로 작용할 수 있으므로, 경제적이지 못하다.In addition, if the secondary stirring speed is less than 2,500 rpm or the stirring time is less than 3 hours, each component in the secondary mixture may not be completely dissolved, which may lead to difficulties in securing dispersibility. If the stirring speed exceeds 3,500 rpm, or If the stirring time exceeds 10 hours, it may act as a factor that only increases manufacturing costs without further effect, making it uneconomical.
이러한 2차 교반시, 30 ~ 45KHz의 주파수 및 15 ~ 25W의 출력 전압 조건으로 초음파 처리를 함께 실시하는 것이 보다 바람직한데, 이는 2차 혼합물 내의 각 성분들에 대한 용해성을 더 향상시키기 위함이다.During this secondary stirring, it is more preferable to carry out ultrasonic treatment at a frequency of 30 to 45 KHz and an output voltage of 15 to 25 W, in order to further improve the solubility of each component in the secondary mixture.
초음파 인가시, 주파수가 30KHz 미만이거나, 출력 전압이 15W 미만일 경우에는 초음파의 인가에 따른 캐비테이션(cavitation) 효과가 미미하여 용해성 향상 효과를 제대로 발휘하기 어렵다. 반대로, 초음파의 주파수가 45KHz를 초과하거나, 또는 출력 전압이 25W를 초과할 경우에는 과도한 초음파 인가로 인하여 2차 혼합물 내의 각 성분들이 손상될 우려가 있으므로, 바람직하지 못하다.When applying ultrasonic waves, if the frequency is less than 30 KHz or the output voltage is less than 15 W, the cavitation effect due to the application of ultrasonic waves is minimal, making it difficult to properly demonstrate the effect of improving solubility. Conversely, when the frequency of ultrasonic waves exceeds 45 KHz or the output voltage exceeds 25 W, it is undesirable because there is a risk that each component in the secondary mixture may be damaged due to excessive application of ultrasonic waves.
화장료 조성물 형성Cosmetic composition formation
화장료 조성물 형성 단계(S140)에서는 1차 혼합물에 2차 혼합물을 혼합하고 교반한 후, 냉각하여 화장료 조성물을 형성한다.In the cosmetic composition forming step (S140), the secondary mixture is mixed with the primary mixture, stirred, and then cooled to form a cosmetic composition.
여기서, 화장료 조성물은 본 단계에서, 화장료 조성물은 인체지방세포배양액 추출물 5 ~ 15 중량%, 유화제 1 ~ 10 중량%, 계면활성제 0.1 ~ 6.0 중량%, 히알루론산 0.5 ~ 7 중량%, 펩타이드 0.01 ~ 5 중량%, 세라마이드 1 ~ 10 중량%, 알로에베라잎즙 0.1 ~ 7.0 중량%, 나이아신아마이드 0.5 ~ 5 중량%, 아데노신 0.1 ~ 5.0 중량%, 스쿠알란 5 ~ 40 중량% 및 나머지 잔량의 정제수를 포함한다.Here, in this step, the cosmetic composition includes 5 to 15% by weight of human fat cell culture fluid extract, 1 to 10% by weight of emulsifier, 0.1 to 6.0% by weight of surfactant, 0.5 to 7% by weight of hyaluronic acid, and 0.01 to 5% by weight of peptide. % by weight, ceramide 1 to 10 wt%, aloe vera leaf juice 0.1 to 7.0 wt%, niacinamide 0.5 to 5 wt%, adenosine 0.1 to 5.0 wt%, squalane 5 to 40 wt%, and the remaining amount of purified water.
또한, 화장료 조성물은 pH 조절제 0.1 ~ 5 중량%, 유화 안정화제 0.01 ~ 5 중량%, 방부제 0.01 ~ 3 중량%, 향료 0.1 ~ 2 중량% 및 N,N'－p－페닐렌비스말레이미드 0.1 ~ 2.0 중량% 중 1종 이상을 더 포함할 수 있다.In addition, the cosmetic composition contains 0.1 to 5% by weight of a pH adjuster, 0.01 to 5% by weight of an emulsion stabilizer, 0.01 to 3% by weight of a preservative, 0.1 to 2% by weight of fragrance, and 0.1 to 0.1% by weight of N,N'-p-phenylenebismaleimide. It may further include one or more of 2.0% by weight.
이상으로, 본 발명의 실시예에 따른 인체지방세포배양액 추출물을 함유한 화장료 조성물 제조 방법이 종료될 수 있다.With this, the method for producing a cosmetic composition containing the human fat cell culture fluid extract according to an embodiment of the present invention can be completed.
상술한 바와 같이, 본 발명의 실시예에 따른 인체지방세포배양액 추출물을 함유한 화장료 조성물 제조 방법은 인체 지방조직에서 유래한 줄기세포 배양액인 인체지방세포배양액 추출물과 펩타이드가 고함량으로 함유되어 맑고 투명한 피부로 유지시켜 피부 개선 효과를 도모할 수 있다.As described above, the method for producing a cosmetic composition containing a human fat cell culture fluid extract according to an embodiment of the present invention contains a high content of human fat cell culture fluid extract, which is a stem cell culture fluid derived from human adipose tissue, and peptides, making it clear and transparent. By maintaining it in the skin, it can achieve a skin improvement effect.
아울러, 본 발명의 실시예에 따른 인체지방세포배양액 추출물을 함유한 화장료 조성물 제조 방법은 고압 유화 처리에 의해, 나노입자 사이즈로 미립자화된 세라마이드 및 스쿠알란에 의해 피부 깊숙이 빠르게 흡수되어 보습과 피부장벽 개선에 도움을 주어 건강한 피부를 만들어 줄 수 있을 뿐만 아니라, 나이아신아마이드와 아데노신이 함유되어 미백 및 주름개선에 탁월한 효과를 발휘한다.In addition, the method for producing a cosmetic composition containing human fat cell culture fluid extract according to an embodiment of the present invention is quickly absorbed deep into the skin by ceramide and squalane finely divided into nanoparticles by high-pressure emulsification treatment to moisturize and improve the skin barrier. Not only does it help create healthy skin, but it also contains niacinamide and adenosine, which are excellent for whitening and wrinkle improvement.
또한, 본 발명의 실시예에 따른 인체지방세포배양액 추출물을 함유한 화장료 조성물 제조 방법은 히알루론산과 알로에베라잎즙이 유효 성분으로 함유되어, 피부 보습 및 진정 효과를 갖는다.In addition, the method for producing a cosmetic composition containing human fat cell culture fluid extract according to an embodiment of the present invention contains hyaluronic acid and aloe vera leaf juice as active ingredients, and has a skin moisturizing and soothing effect.
실시예Example
이하, 본 발명의 바람직한 실시예를 통해 본 발명의 구성 및 작용을 더욱 상세히 설명하기로 한다. 다만, 이는 본 발명의 바람직한 예시로 제시된 것이며 어떠한 의미로도 이에 의해 본 발명이 제한되는 것으로 해석될 수는 없다.Hereinafter, the configuration and operation of the present invention will be described in more detail through preferred embodiments of the present invention. However, this is presented as a preferred example of the present invention and should not be construed as limiting the present invention in any way.
여기에 기재되지 않은 내용은 이 기술 분야에서 숙련된 자이면 충분히 기술적으로 유추할 수 있는 것이므로 그 설명을 생략하기로 한다.Any information not described here can be technically inferred by anyone skilled in the art, so description thereof will be omitted.
1) 화장료 조성물 제조1) Manufacturing cosmetic composition
실시예 1Example 1
표 1에 기재된 성분 및 성분비로 수상의 화장료 각 원료를 계량하고, 1,200rpm의 속도로 60분 동안 교반하면서 75℃까지 1차 가열하여 1차 혼합물을 제조하였다.Each cosmetic raw material in the water phase was weighed using the ingredients and ingredient ratios shown in Table 1, and the primary mixture was prepared by first heating to 75°C while stirring at a speed of 1,200 rpm for 60 minutes.
다음으로, 세라마이드 및 스쿠알란을 65℃ 조건에서 1,800bar의 압력으로 유지되는 고압 유화기 내에 4회 통과시킨 후, 20℃까지 냉각하여 70nm의 평균 입경으로 미립자화된 세라마이드 및 스쿠알란을 각각 수득하였다.Next, ceramide and squalane were passed four times in a high-pressure emulsifier maintained at a pressure of 1,800 bar at 65°C, and then cooled to 20°C to obtain microparticles of ceramide and squalane with an average particle diameter of 70nm, respectively.
다음으로, 미립자화된 세라마이드 및 스쿠알란을 유상의 화장료 원료에 혼합하고 2,800rpm의 속도로 교반하면서 90℃ 조건에서 6시간 동안 2차 가열하여 2차 혼합물을 제조하였다.Next, a secondary mixture was prepared by mixing micronized ceramide and squalane with oily cosmetic raw materials and secondary heating at 90°C for 6 hours while stirring at a speed of 2,800 rpm.
다음으로, 수상의 1차 혼합물과 유상의 2차 혼합물을 호모믹서를 이용해 2,500rpm의 속도로 30분 동안 교반한 후, 20℃까지 냉각하여 화장료 조성물을 제조하였다.Next, the primary mixture of the water phase and the secondary mixture of the oil phase were stirred for 30 minutes at a speed of 2,500 rpm using a homomixer, and then cooled to 20°C to prepare a cosmetic composition.
실시예 2Example 2
세라마이드 및 스쿠알란을 60℃ 조건에서 1,700bar의 압력으로 유지되는 고압 유화기 내에 3회 통과시킨 후, 20℃까지 냉각하여 65nm의 평균 입경으로 미립자화된 세라마이드 및 스쿠알란을 각각 수득한 것을 제외하고는 실시예 1과 동일한 방법으로 화장료 조성물을 제조하였다.Ceramide and squalane were passed through a high-pressure emulsifier maintained at a pressure of 1,700 bar at 60°C three times, then cooled to 20°C to obtain microparticles of ceramide and squalane with an average particle diameter of 65nm, respectively. A cosmetic composition was prepared in the same manner as Example 1.
실시예 3Example 3
세라마이드 및 스쿠알란을 70℃ 조건에서 1,900bar의 압력으로 유지되는 고압 유화기 내에 5회 통과시킨 후, 20℃까지 냉각하여 84nm의 평균 입경으로 미립자화된 세라마이드 및 스쿠알란을 각각 수득한 것을 제외하고는 실시예 1과 동일한 방법으로 화장료 조성물을 제조하였다.Ceramide and squalane were passed through a high-pressure emulsifier maintained at a pressure of 1,900 bar at 70°C five times, and then cooled to 20°C to obtain microparticles of ceramide and squalane with an average particle diameter of 84nm, respectively. A cosmetic composition was prepared in the same manner as Example 1.
실시예 4Example 4
미립자화된 세라마이드 및 스쿠알란을 유상의 화장료 원료에 혼합하고 2,700rpm의 속도로 교반하면서, 40KHz의 주파수 및 20W의 출력 전압 조건으로 초음파 처리를 함께 실시한 후, 90℃ 조건에서 7시간 동안 2차 가열하여 2차 혼합물을 제조한 것을 제외하고는 실시예 1과 동일한 방법으로 화장료 조성물을 제조하였다.Micronized ceramide and squalane are mixed with oily cosmetic raw materials, stirred at a speed of 2,700 rpm, ultrasonicated at a frequency of 40 KHz and output voltage of 20 W, and then heated for a second time at 90°C for 7 hours. A cosmetic composition was prepared in the same manner as Example 1, except that a secondary mixture was prepared.
실시예 5Example 5
미립자화된 세라마이드 및 스쿠알란을 유상의 화장료 원료에 혼합하고 2,800rpm의 속도로 교반하면서, 35KHz의 주파수 및 18W의 출력 전압 조건으로 초음파 처리를 함께 실시한 후, 95℃ 조건에서 8시간 동안 2차 가열하여 2차 혼합물을 제조한 것을 제외하고는 실시예 1과 동일한 방법으로 화장료 조성물을 제조하였다.Micronized ceramide and squalane are mixed with oily cosmetic raw materials and ultrasonicated at a frequency of 35 KHz and output voltage of 18 W while stirring at a speed of 2,800 rpm, followed by secondary heating at 95°C for 8 hours. A cosmetic composition was prepared in the same manner as Example 1, except that a secondary mixture was prepared.
실시예 6Example 6
2차 혼합물 제조시, 유상의 화장료 원료에 N,N'－p－페닐렌비스말레이미드를 더 첨가한 것을 제외하고는 실시예 1과 동일한 방법으로 화장료 조성물을 제조하였다.When preparing the secondary mixture, a cosmetic composition was prepared in the same manner as Example 1, except that N,N'-p-phenylenebismaleimide was further added to the oily cosmetic raw material.
비교예 1Comparative Example 1
표 1에 기재된 성분 및 성분비로 수상의 화장료 각 원료를 계량하고, 1,200rpm의 속도로 50분 동안 교반하면서 70℃까지 1차 가열하여 1차 혼합물을 제조하였다.Each cosmetic raw material in the water phase was weighed using the ingredients and ingredient ratios shown in Table 1, and the primary mixture was prepared by first heating to 70°C while stirring at a speed of 1,200 rpm for 50 minutes.
다음으로, 유상의 화장료 원료에 혼합하고 2,500rpm의 속도로 교반한 후, 90℃ 조건에서 6시간 동안 2차 가열하여 2차 혼합물을 제조하였다.Next, it was mixed with oily cosmetic raw materials, stirred at a speed of 2,500 rpm, and then heated for a second time at 90°C for 6 hours to prepare a secondary mixture.
다음으로, 수상의 1차 혼합물과 유상의 2차 혼합물을 호모믹서를 이용해 2,500rpm의 속도로 30분 동안 교반한 후, 20℃까지 냉각하여 화장료 조성물을 제조하였다.Next, the primary mixture of the water phase and the secondary mixture of the oil phase were stirred for 30 minutes at a speed of 2,500 rpm using a homomixer, and then cooled to 20°C to prepare a cosmetic composition.
2) 주름개선 평가2) Wrinkle improvement evaluation
표 2는 실시예 1 ~ 6 및 비교예 1에 따라 제조된 화장료 조성물의 사용에 따른 주름개선 평가 결과를 나타낸 것이다. 이때, 주름개선 평가는 피시험자의 4주 후 링클 스몰(Wrinkles small) 값의 변화량을 분석하였으며, 주름 개선 효과가 우수할수록 링클 스몰(Wrinkles small) 값 변화량이 크다.Table 2 shows the results of wrinkle improvement evaluation according to the use of the cosmetic composition prepared according to Examples 1 to 6 and Comparative Example 1. At this time, the wrinkle improvement evaluation analyzed the amount of change in the Wrinkles small value of the test subject after 4 weeks. The better the wrinkle improvement effect, the greater the change in the Wrinkles small value.
주름개선 평가를 위해, 30 ~ 50대의 성인 여성을 대상으로 7개의 그룹으로 나누고, 피시험자는 4주 동안 매일 아침 및 저녁에 세안한 후 각 그룹별로 실시예 1 ~ 6 및 비교예 1에 따라 제조된 화장료 조성물을 앰플 타입으로 제형화한 화장료를 안면에 고르게 도포하여 충분히 흡수시켰다. 주름개선 평가 장치로는 ANTERA 3D(Miravex, Ireland)를 이용하였으며, 기기측정은 시험물질 사용 전과 4주 사용 후 시점에서 이루어졌다. 피시험자의 왼쪽 눈꼬리 부위를 측정하였고, 측정의 재현성을 위하여 시험 물질 사용 전에 측정한 이미지와 오버랩시켜 동일부위를 측정하였다. 촬영된 이미지는 ANTERA 3D 전용 소프트웨어인 ANTERA 프로 소프트웨어(pro software)를 이용하여 매칭시킨 후, 일치된 측정부위를 분석에 사용하였다.For wrinkle improvement evaluation, adult women in their 30s to 50s were divided into 7 groups, and the test subjects washed their face every morning and evening for 4 weeks, and then each group was treated with the product prepared according to Examples 1 to 6 and Comparative Example 1. The cosmetic composition formulated in an ampoule type was evenly applied to the face and fully absorbed. ANTERA 3D (Miravex, Ireland) was used as a wrinkle improvement evaluation device, and measurements were made before and after 4 weeks of use of the test substance. The left corner of the test subject's eye was measured, and for reproducibility of measurements, the same area was measured by overlapping with the image measured before using the test substance. The captured images are matched using ANTERA pro software, a dedicated software for ANTERA 3D, and then the matched measurement area is measured. used for analysis.
표 1 및 표 2에 나타낸 바와 같이, 실시예 1 ~ 6의 시료를 제형화한 화장료가 비교예 1의 시료를 제형화한 화장료에 비하여, 피부 주름 개선 효과가 뚜렷하게 개선된 것을 확인할 수 있다. 특히, 실시예 5 ~ 6의 시료를 제형화한 화장료가 피부 주름 개선 효과가 가장 우수한 것을 확인하였다.As shown in Tables 1 and 2, it can be seen that the skin wrinkle improvement effect of the cosmetics formulated with the samples of Examples 1 to 6 was clearly improved compared to the cosmetics formulated with the samples of Comparative Example 1. In particular, it was confirmed that the cosmetics formulated from the samples of Examples 5 to 6 had the best effect on improving skin wrinkles.
3) 미백 및 보습 평가3) Whitening and moisturizing evaluation
표 3은 실시예 1 ~ 6 및 비교예 1에 따라 제조된 화장료 조성물의 사용에 따른 미백 및 보습 평가 결과를 나타낸 것이다. 20 ~ 40대의 여성을 7개의 그룹으로 나누고, 각 그룹별로 실시예 1 ~ 6 및 비교예 1에 따라 제조된 화장료 조성물을 앰플 타입으로 제형화한 화장료를 각각 도포하였다. 눈가를 중심으로 아침 및 저녁으로 하루 2회씩 6주 동안 앰플 타입으로 제형화한 화장료를 안면에 고르게 바르도록 한 후, 5점 척도법(5: 아주 우수, 4: 우수, 3: 보통, 2: 나쁨, 1: 매우 나쁨)에 따라 점수를 매기도록 하고 평균 값으로 나타내었다.Table 3 shows the whitening and moisturizing evaluation results according to the use of the cosmetic compositions prepared according to Examples 1 to 6 and Comparative Example 1. Women in their 20s to 40s were divided into 7 groups, and each group was applied a cosmetic composition formulated in an ampoule type according to Examples 1 to 6 and Comparative Example 1. Apply cosmetics formulated in an ampoule type evenly on the face, focusing on the eye area, twice a day, morning and evening, for 6 weeks. Then, use a 5-point scale (5: very good, 4: excellent, 3: average, 2: poor). , 1: very bad) and expressed as the average value.
표 1 및 표 3에 나타낸 바와 같이, 실시예 1 ~ 6의 시료를 제형화한 화장료가 비교예 1의 시료를 제형화한 화장료에 비하여, 미백 및 보습력에서 탁월한 효능을 나타내는 것을 확인하였다.As shown in Tables 1 and 3, it was confirmed that the cosmetics formulated with the samples of Examples 1 to 6 exhibited superior efficacy in whitening and moisturizing compared to the cosmetics formulated with the samples of Comparative Example 1.
또한, 실시예 1 ~ 6의 시료를 제형화한 화장료가 비교예 1의 시료를 제형화한 화장료에 비하여, 끈적임이 없는 것을 확인하였다. 특히, 실시예 6의 시료를 제형화한 화장료의 경우, 끈적임이 전혀 없어 우수한 사용감을 나타내는 것을 확인하였는데, 이는 N,N'－p－페닐렌비스말레이미드가 첨가된데 기인한 것으로 판단된다.In addition, it was confirmed that the cosmetics formulated from the samples of Examples 1 to 6 were not sticky compared to the cosmetics formulated from the samples of Comparative Example 1. In particular, in the case of the cosmetic formulated with the sample of Example 6, it was confirmed that there was no stickiness at all, showing an excellent feeling of use, which was believed to be due to the addition of N,N'-p-phenylenebismaleimide.
이상과 같이 본 발명의 실시예와 비교예에 대하여 상세히 설명하였으나, 본 발명의 권리범위는 이에 한정되지 않으며, 본 발명의 실시예와 실질적으로 균등의 범위에 있는 것까지 본 발명의 권리범위가 미친다.Although the examples and comparative examples of the present invention have been described in detail as described above, the scope of the rights of the present invention is not limited thereto, and the scope of the rights of the present invention extends to the scope substantially equivalent to the examples of the present invention. .
S110 : 1차 혼합물 형성 단계
S120 : 고압 유화 단계
S130 : 2차 혼합물 형성 단계
S140 : 화장료 조성물 형성 단계S110: First mixture formation step
S120: High pressure emulsification step
S130: Secondary mixture formation step
S140: Cosmetic composition formation step
Claims (7)
유화제 1 ~ 10 중량%;
계면활성제 0.1 ~ 6.0 중량%;
히알루론산 0.5 ~ 7 중량%;
펩타이드 0.01 ~ 5 중량%:
세라마이드 1 ~ 10 중량%;
알로에베라잎즙 0.1 ~ 7.0 중량%;
나이아신아마이드 0.5 ~ 5 중량%;
아데노신 0.1 ~ 5.0 중량%;
스쿠알란 5 ~ 40 중량%;
pH 조절제 0.1 ~ 5 중량%;
유화 안정화제 0.01 ~ 5 중량%;
방부제 0.01 ~ 3 중량%;
N,N'－p－페닐렌비스말레이미드 0.1 ~ 2.0 중량%; 및
나머지 잔량의 정제수;를 포함하며,
상기 세라마이드 및 스쿠알란 각각은 고압 유화기를 통과시키는 고압 유화 처리에 의해, 나노입자 사이즈로 미립자화되어, 10 ~ 100nm의 평균 입경을 갖는 것을 특징으로 하는 인체지방세포배양액 추출물을 함유한 화장료 조성물.5 to 15% by weight of human fat cell culture fluid extract;
1 to 10% by weight of emulsifier;
Surfactant 0.1 to 6.0% by weight;
Hyaluronic acid 0.5 to 7% by weight;
Peptide 0.01 to 5% by weight:
1 to 10% by weight of ceramide;
Aloe vera leaf juice 0.1 to 7.0% by weight;
Niacinamide 0.5 to 5% by weight;
Adenosine 0.1 to 5.0% by weight;
5 to 40% by weight of squalane;
pH adjuster 0.1 to 5% by weight;
Emulsion stabilizer 0.01 to 5% by weight;
Preservative 0.01 to 3% by weight;
N,N'-p-phenylenebismaleimide 0.1 to 2.0% by weight; and
Contains the remaining amount of purified water,
Each of the ceramide and squalane is miniaturized into nanoparticles by high-pressure emulsification treatment through a high-pressure emulsifier, and has an average particle size of 10 to 100 nm. A cosmetic composition containing an extract of human fat cell culture fluid.
상기 펩타이드는
카퍼펩타이드-1(Copper Tripeptide-1), 팔미토일트리펩타이드-1(Palmitoyl Tripeptide-1), 아세틸헥사펩타이드-8, 에스에이치-올리고펩타이드-1 및 알에이치-올리고펩타이드-2 중 선택된 1종 이상을 포함하는 것을 특징으로 하는 인체지방세포배양액 추출물을 함유한 화장료 조성물.According to paragraph 1,
The peptide is
One or more types selected from Copper Tripeptide-1, Palmitoyl Tripeptide-1, Acetylhexapeptide-8, SH-Oligopeptide-1, and RH-Oligopeptide-2 A cosmetic composition containing an extract of human fat cell culture fluid, characterized in that it contains.
상기 화장료 조성물은
향료 0.1 ~ 2 중량%;
를 더 포함하는 것을 특징으로 하는 인체지방세포배양액 추출물을 함유한 화장료 조성물.According to paragraph 1,
The cosmetic composition is
Fragrance 0.1 to 2% by weight;
A cosmetic composition containing a human fat cell culture fluid extract, characterized in that it further comprises.
(b) 세라마이드 및 스쿠알란을 고압 유화기를 통과시키는 고압 유화를 실시한 후, 냉각하여 나노입자 사이즈로 미립자화된 세라마이드 및 스쿠알란을 수득하는 단계;
(c) 상기 나노입자 사이즈로 미립자화된 세라마이드 및 스쿠알란을 인체지방줄기세포배양액 추출물을 포함하는 유상의 화장료 원료에 혼합하고 교반하면서 2차 가열하여 2차 혼합물을 형성하는 단계; 및
(d) 상기 1차 혼합물에 2차 혼합물을 혼합하고 교반한 후, 냉각하여 화장료 조성물을 형성하는 단계;를 포함하며,
상기 (d) 단계 이후, 상기 화장료 조성물은 인체지방세포배양액 추출물 5 ~ 15 중량%, 유화제 1 ~ 10 중량%, 계면활성제 0.1 ~ 6.0 중량%, 히알루론산 0.5 ~ 7 중량%, 펩타이드 0.01 ~ 5 중량%, 세라마이드 1 ~ 10 중량%, 알로에베라잎즙 0.1 ~ 7.0 중량%, 나이아신아마이드 0.5 ~ 5 중량%, 아데노신 0.1 ~ 5.0 중량%, 스쿠알란 5 ~ 40 중량%, pH 조절제 0.1 ~ 5 중량%, 유화 안정화제 0.01 ~ 5 중량%, 방부제 0.01 ~ 3 중량%, N,N'－p－페닐렌비스말레이미드 0.1 ~ 2.0 중량% 및 나머지 잔량의 정제수를 포함하며,
상기 (b) 단계에서, 상기 나노입자 사이즈로 미립자화된 세라미이드 및 스쿠알란 각각은 10 ~ 100nm의 평균 입경을 갖는 것을 특징으로 하는 인체지방세포배양액 추출물을 함유한 화장료 조성물 제조 방법.(a) forming a primary mixture by first heating the cosmetic raw materials in the water phase by weighing, mixing, and stirring;
(b) performing high-pressure emulsification of ceramide and squalane through a high-pressure emulsifier, followed by cooling to obtain ceramide and squalane finely divided into nanoparticles;
(c) mixing the ceramide and squalane micronized to the nanoparticle size with oily cosmetic raw materials containing human adipose stem cell culture fluid extract and secondary heating while stirring to form a secondary mixture; and
(d) mixing the secondary mixture with the primary mixture, stirring the mixture, and then cooling to form a cosmetic composition,
After step (d), the cosmetic composition contains 5 to 15% by weight of human fat cell culture fluid extract, 1 to 10% by weight of emulsifier, 0.1 to 6.0% by weight of surfactant, 0.5 to 7% by weight of hyaluronic acid, and 0.01 to 5% by weight of peptide. %, ceramide 1 ~ 10% by weight, aloe vera leaf juice 0.1 ~ 7.0% by weight, niacinamide 0.5 ~ 5% by weight, adenosine 0.1 ~ 5.0% by weight, squalane 5 ~ 40% by weight, pH adjuster 0.1 ~ 5% by weight, emulsion stability It contains 0.01 to 5% by weight of topical agent, 0.01 to 3% by weight of preservative, 0.1 to 2.0% by weight of N,N'-p-phenylenebismaleimide, and the remaining amount of purified water,
In step (b), each of the ceramide and squalane micronized to the nanoparticle size has an average particle diameter of 10 to 100 nm.
상기 (b) 단계에서,
상기 고압 유화는
50 ~ 80℃ 조건에서 700 ~ 2,500bar의 압력으로 실시하는 것을 특징으로 하는 인체지방세포배양액 추출물을 함유한 화장료 조성물 제조 방법.According to clause 5,
In step (b) above,
The high pressure emulsification is
A method for producing a cosmetic composition containing human fat cell culture fluid extract, characterized in that it is carried out at a pressure of 700 to 2,500 bar under conditions of 50 to 80°C.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020230009796A KR102594510B1 (en) | 2023-01-26 | 2023-01-26 | Cosmetic composition including human adipocyte conditioned media extract and manufacturing method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020230009796A KR102594510B1 (en) | 2023-01-26 | 2023-01-26 | Cosmetic composition including human adipocyte conditioned media extract and manufacturing method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR102594510B1 true KR102594510B1 (en) | 2023-10-25 |
Family
ID=88515560
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020230009796A KR102594510B1 (en) | 2023-01-26 | 2023-01-26 | Cosmetic composition including human adipocyte conditioned media extract and manufacturing method thereof |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102594510B1 (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20090063789A (en) | 2007-12-14 | 2009-06-18 | 코스맥스 주식회사 | Cosmetic compositions containing extract of (sorbus alnifolia (s. et z.) k. koch) used for antiwrinkle |
| KR20160086253A (en) * | 2015-01-08 | 2016-07-19 | 한양대학교 에리카산학협력단 | Cosmetic composition containing exosomes extracted from stem cell for skin whitening, antiwrinkle or regeneration |
| KR102265730B1 (en) * | 2020-11-06 | 2021-06-17 | 주식회사 본에스티스 | cosmetic composition for skin wrinkle improvement and whitening facial skin |
| KR20220091739A (en) * | 2020-12-24 | 2022-07-01 | 주식회사 넥스텍인터내셔널 | Translucent nanoemulsion containing natural ceramide and cosmetic composition including the same |
-
2023
- 2023-01-26 KR KR1020230009796A patent/KR102594510B1/en active IP Right Grant
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20090063789A (en) | 2007-12-14 | 2009-06-18 | 코스맥스 주식회사 | Cosmetic compositions containing extract of (sorbus alnifolia (s. et z.) k. koch) used for antiwrinkle |
| KR20160086253A (en) * | 2015-01-08 | 2016-07-19 | 한양대학교 에리카산학협력단 | Cosmetic composition containing exosomes extracted from stem cell for skin whitening, antiwrinkle or regeneration |
| KR102265730B1 (en) * | 2020-11-06 | 2021-06-17 | 주식회사 본에스티스 | cosmetic composition for skin wrinkle improvement and whitening facial skin |
| KR20220091739A (en) * | 2020-12-24 | 2022-07-01 | 주식회사 넥스텍인터내셔널 | Translucent nanoemulsion containing natural ceramide and cosmetic composition including the same |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI352595B (en) | Cosmetic and cosmeceutical compositions for restor | |
| KR101391834B1 (en) | Whitening cosmetic compounds and method for fabricating the same | |
| KR20120135358A (en) | Cosmetic and external skin preparation, and medical instrument | |
| US20210393507A1 (en) | Extemporaneous cosmetic and/or dermatological preparations | |
| KR20160141297A (en) | Cosmetic composition for skin regeneration containing horse fat having an effect on skin elasticity and method for the manufacture thereof | |
| JP2003155238A (en) | Skin care preparation | |
| JP5329830B2 (en) | SCF secretion inhibitor and sebum secretion inhibitor | |
| JP2017193506A (en) | Skin Cosmetic | |
| KR102594510B1 (en) | Cosmetic composition including human adipocyte conditioned media extract and manufacturing method thereof | |
| JP2003137768A (en) | Antiaging agent | |
| TW201808261A (en) | Skin care products and uses thereof | |
| JP5226200B2 (en) | Sulfated glycosaminoglycan production promoter and skin external preparation containing the same | |
| WO2006028199A1 (en) | Skin-lightening preparation for external use and method of skin lightening | |
| KR102479550B1 (en) | Skin elasticity improvement cosmetics and manufacturing method thereof | |
| KR102267938B1 (en) | Moisturizing cosmetics that improve skin absorption, including asiatic pennywort extract, anemarrhena asphodeloides root extract, apricot seed oil, and peptides having antioxidant activity, and a method for manufacturing the same | |
| KR102072297B1 (en) | A cosmetic composition comprising a vegetable protein-derived surfactant | |
| KR20090028275A (en) | Cosmetic materials for anti-aging and winkle reducing effects having essential oil complex as its principal ingredient, and the manufacturing method thereof | |
| JP2000159656A (en) | Agent for promoting synthesis of collagen | |
| KR102594145B1 (en) | Nanoemulsion of translucent formulation containing natural ceramide and manufacturing method thereof and manufacturing method of customized cosmetics including the same | |
| JP2009249366A (en) | Collagen production promotor and anti-aging skin preparation for external use | |
| KR102593587B1 (en) | Manufacturing method of foot care cosmetic composition for preventing and improving atopic skin disease | |
| RU2805147C2 (en) | Biological additive to be added to cosmetic and healing products, a method of its production, cosmetic and healing compositions based on its | |
| RU2119790C1 (en) | Agent for biological skin rejuvenation | |
| US20200214969A1 (en) | Compositions and Methods for Topical Skin Treatment | |
| JP2014214094A (en) | Cosmetic composition containing liposome including culture solution extract of stem cells derived from human |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |